![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ 08854
3To whom correspondence should be addressed. E-mail: csyang{at}rci.rutgers.edu.
Consumption of tea (Camellia sinensis) has been suggested to prevent cancer, heart disease and other diseases. Animal studies have shown that tea and tea constituents inhibit carcinogenesis of the skin, lung, oral cavity, esophagus, stomach, liver, prostate and other organs. In some studies, the inhibition correlated with an increase in tumor cell apoptosis and a decrease in cell proliferation. Studies with human cancer cell lines have demonstrated that epigallocatechin-3-gallate (EGCG), a major tea polyphenol, inhibits mitogen-activated protein kinases, cyclin-dependent kinases, growth factor-related cell signaling, activation of activator protein 1 (AP-1) and nuclear factor 
B (NFB), topoisomerase I and matrix metalloproteinases as well as other potential targets. Although some studies report effects of EGCG at submicromolar levels, most experiments require concentrations of >10 or 20 µmol/L to demonstrate the effect. In humans, tea polyphenols undergo glucuronidation, sulfation, methylation, and ring fission. The peak plasma concentration of EGCG is 
1 µmol/L. The possible relevance of each of the proposed mechanisms to human cancer prevention is discussed in light of current bioavailability data for tea polyphenols and the potential limitations of animal models of carcinogenesis. Such discussion, it is hoped, will clarify some misunderstandings of cancer prevention by tea and stimulate new research efforts.
KEY WORDS: • tea • catechins • theaflavins • cancer prevention • bioavailability
This article has been cited by other articles:
|
|
 |
|
  P. A. RAGAZZON, J. ILEY, and S. MISSAILIDIS Structure-activity Studies of the Binding of the Flavonoid Scaffold to DNA Anticancer Res, June 1, 2009; 29(6): 2285 - 2293. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Lambert, S.-J. Kwon, J. Ju, M. Bose, M.-J. Lee, J. Hong, X. Hao, and C. S. Yang Effect of genistein on the bioavailability and intestinal cancer chemopreventive activity of (-)-epigallocatechin-3-gallate Carcinogenesis, October 1, 2008; 29(10): 2019 - 2024. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Bose, J. D. Lambert, J. Ju, K. R. Reuhl, S. A. Shapses, and C. S. Yang The Major Green Tea Polyphenol, (-)-Epigallocatechin-3-Gallate, Inhibits Obesity, Metabolic Syndrome, and Fatty Liver Disease in High-Fat-Fed Mice J. Nutr., September 1, 2008; 138(9): 1677 - 1683. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Xiao, X. Hao, B. Simi, J. Ju, H. Jiang, B. S. Reddy, and C. S. Yang Green tea polyphenols inhibit colorectal aberrant crypt foci (ACF) formation and prevent oncogenic changes in dysplastic ACF in azoxymethane-treated F344 rats Carcinogenesis, January 1, 2008; 29(1): 113 - 119. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. F. Collins, H.-Y. Liu, J. Pi, Z. Liu, M. J. Quon, and W. Cao Epigallocatechin-3-gallate (EGCG), A Green Tea Polyphenol, Suppresses Hepatic Gluconeogenesis through 5'-AMP-activated Protein Kinase J. Biol. Chem., October 12, 2007; 282(41): 30143 - 30149. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. McKay and J. B. Blumberg Roles for Epigallocatechin Gallate in Cardiovascular Disease and Obesity: An Introduction J. Am. Coll. Nutr., August 1, 2007; 26(4): 362S - 365S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Wolfram Effects of Green Tea and EGCG on Cardiovascular and Metabolic Health J. Am. Coll. Nutr., August 1, 2007; 26(4): 373S - 388S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Lambert, S. Sang, J. Hong, S.-J. Kwon, M.-J. Lee, C.-T. Ho, and C. S. Yang Peracetylation as a Means of Enhancing in Vitro Bioactivity and Bioavailability of Epigallocatechin-3-Gallate Drug Metab. Dispos., December 1, 2006; 34(12): 2111 - 2116. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Lu, J. Liao, G. Yang, K. R. Reuhl, X. Hao, and C. S. Yang Inhibition of Adenoma Progression to Adenocarcinoma in a 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanone-Induced Lung Tumorigenesis Model in A/J Mice by Tea Polyphenols and Caffeine Cancer Res., December 1, 2006; 66(23): 11494 - 11501. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Shammas, P. Neri, H. Koley, R. B. Batchu, R. C. Bertheau, V. Munshi, R. Prabhala, M. Fulciniti, Y. t. Tai, S. P. Treon, et al. Specific killing of multiple myeloma cells by (-)-epigallocatechin-3-gallate extracted from green tea: biologic activity and therapeutic implications Blood, October 15, 2006; 108(8): 2804 - 2810. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Henning, W. Aronson, Y. Niu, F. Conde, N. H. Lee, N. P. Seeram, R.-P. Lee, J. Lu, D. M. Harris, A. Moro, et al. Tea Polyphenols and Theaflavins Are Present in Prostate Tissue of Humans and Mice after Green and Black Tea Consumption J. Nutr., July 1, 2006; 136(7): 1839 - 1843. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Luo, L. Tang, M. Tang, M. Billam, T. Huang, J. Yu, Z. Wei, Y. Liang, K. Wang, Z.-Q. Zhang, et al. Phase IIa chemoprevention trial of green tea polyphenols in high-risk individuals of liver cancer: modulation of urinary excretion of green tea polyphenols and 8-hydroxydeoxyguanosine Carcinogenesis, February 1, 2006; 27(2): 262 - 268. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Lambert, M.-J. Lee, L. Diamond, J. Ju, J. Hong, M. Bose, H. L. Newmark, and C. S. Yang DOSE-DEPENDENT LEVELS OF EPIGALLOCATECHIN-3-GALLATE IN HUMAN COLON CANCER CELLS AND MOUSE PLASMA AND TISSUES Drug Metab. Dispos., January 1, 2006; 34(1): 8 - 11. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ermakova, B. Y. Choi, H. S. Choi, B. S. Kang, A. M. Bode, and Z. Dong The Intermediate Filament Protein Vimentin Is a New Target for Epigallocatechin Gallate J. Biol. Chem., April 29, 2005; 280(17): 16882 - 16890. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Paul, C. S. Hayes, A. Kim, M. Athar, and S. K. Gilmour Elevated polyamines lead to selective induction of apoptosis and inhibition of tumorigenesis by (-)-epigallocatechin-3-gallate (EGCG) in ODC/Ras transgenic mice Carcinogenesis, January 1, 2005; 26(1): 119 - 124. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M Henning, Y. Niu, N. H Lee, G. D Thames, R. R Minutti, H. Wang, V. L. W Go, and D. Heber Bioavailability and antioxidant activity of tea flavanols after consumption of green tea, black tea, or a green tea extract supplement Am. J. Clinical Nutrition, December 1, 2004; 80(6): 1558 - 1564. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Lambert, J. Hong, D. H. Kim, V. M. Mishin, and C. S. Yang Piperine Enhances the Bioavailability of the Tea Polyphenol (-)-Epigallocatechin-3-gallate in Mice J. Nutr., August 1, 2004; 134(8): 1948 - 1952. [Abstract] [Full Text] [PDF]
|
|
